Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma (OS) is a bone cancer often linked to TP53 gene alterations.
• The precise molecular pathways driving OS development after p53 inactivation are not fully understood.
• p53-deficient mouse models are crucial for studying osteosarcomagenesis.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying osteosarcoma development in the absence of p53.
• To investigate the role of RUNX3 and Myc in p53-deficient osteosarcoma.
• To explore potential therapeutic strategies targeting this pathway.

Main Methods:

• Analysis of RUNX3 and Myc expression in human and mouse OS samples.
• Investigating the regulatory relationship between Runx3, Myc, and p53 deficiency.
• Utilizing gene editing (disruption of mR1 site) and knockdown techniques.
• Testing the efficacy of Runx inhibitors in OS mouse models.

Main Results:

• Elevated RUNX3 expression was observed in p53-deficient human and mouse OS.
• Runx3 was found to upregulate Myc expression in a p53-dependent manner via the mR1 promoter site.
• Reducing Myc levels by targeting mR1 or Runx3 decreased OS cell tumorigenicity and tumor progression in mice.
• Runx inhibitors demonstrated therapeutic benefits in OS mouse models.

Conclusions:

• p53 deficiency facilitates osteosarcomagenesis by enabling Runx3 to induce oncogenic Myc expression.
• The Runx3-Myc axis represents a critical pathway in p53-deficient osteosarcoma.
• Targeting Runx3 or Myc may offer a viable therapeutic approach for osteosarcoma.